Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (BHC)
NYSE:BHC
BHC Stock Chart & Stats
$6.61
-$0.02(-0.25%)
At close: 4:00 PM EST
$6.61
-$0.02(-0.25%)
Day’s Range― - ―
52-Week Range$4.25 - $9.85
Previous Close$7.83
Volume991.97K
Average Volume (3M)1.58M
Market Cap
$2.50B
Enterprise Value$31.91B
Total Cash (Recent Filing)$1.73B
Total Debt (Recent Filing)$21.74B
Price to Earnings (P/E)7.0
Beta0.81
Next Earnings
Feb 25, 2026EPS Estimate
1.25Last Dividend Ex-Date
Nov 10, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)1.15
Shares Outstanding370,516,940
10 Day Avg. Volume1,248,182
30 Day Avg. Volume1,583,757
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap12.75
Enterprise Value/Revenue3.24
Enterprise Value/Gross Profit4.58
Enterprise Value/Ebitda10.64
Forecast
1Y Price Target
$8.33Price Target Upside26.02% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Direct-to-Consumer CampaignXifaxan sales exceeded estimates, boosted by a successful direct-to-consumer campaign.
Profit GuidanceThe company's 2025 profit guidance has been raised, indicating optimism in future earnings.
Revenue GrowthBausch & Lomb sales were higher than anticipated, contributing to overall revenue growth.
Bears Say
Earnings PerformanceOperating income and EPS were below expectations due to higher SG&A spending and increased interest expenses.
Future ExpensesFavorable Q3 SG&A spending is not likely to recur, suggesting a potential increase in future expenses.
Interest ExpenseInterest expense was significantly higher than estimated due to refinancing debt at less favorable rates.
Bausch Health Companies News
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was $4.25 and its highest was $9.85 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $2.50B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Feb 25, 2026 which is in 111 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Oct 29, 2025. The company reported $1.153 earnings per share for the quarter, beating the consensus estimate of $1.053 by $0.1.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of $1 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 1.25.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 370,516,940 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of $1.153 in its last earnings report, beating expectations of $1.053. Following the earnings report the stock price went up 12.034%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in BHC
Bausch Health Companies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.33 (26.02% Upside)
$8.33 (26.02% Upside)
Hedge Fund Trend
Increased
By 11.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $333.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.91%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
BHC Company Deck
BHC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with multiple quarters of revenue and EBITDA growth, significant debt reduction, and strong product-level performance. However, some challenges remain in international markets and specific segments.View all BHC earnings summariesBHC Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical
BHC Stock 12 Month Forecast
Average Price Target
$8.33
▲(26.02% Upside)
Technical Analysis
Theratechnologies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Cronos Group
―
HLS Therapeutics Inc
―
Ownership Overview
20.25% Insiders
2.96% Mutual Funds
0.02% Other Institutional Investors
71.82% Public Companies and
Individual Investors